Status of HIV and hepatitis C virus infections among prisoners in the Middle East and North Africa: review and synthesis. by Heijnen, Marieke et al.
Review article
Status of HIV and hepatitis C virus infections among prisoners
in the Middle East and North Africa: review and synthesis
Marieke Heijnen§,1,2, Ghina R Mumtaz1,3 and Laith J Abu-Raddad1,2,4
§Corresponding author: Marieke Heijnen, Infectious Disease Epidemiology Group, Weill Cornell Medicine  Qatar, Cornell University, Qatar Foundation  Education
City, P.O. Box 24144, Doha, Qatar. Tel:(974) 4492 8406. Fax:(974) 4492-8422. (amh3003@qatar-med.cornell.edu; marieke.heijnen@gmail.com)
Abstract
Introduction: The status of HIV and hepatitis C virus (HCV) infections among incarcerated populations in the Middle East and
North Africa (MENA) and the links between prisons and the HIV epidemic are poorly understood. This review synthesized
available HIV and HCV data in prisons in MENA and highlighted opportunities for action.
Methods: The review was based on data generated through the systematic searches of the MENA HIV/AIDS Epidemiology
Synthesis Project (2003 to December 15, 2015) and the MENA HCV Epidemiology Synthesis Project (2011 to December 15,
2015). Sources of data included peer-reviewed publications and country-level reports and databases.
Results and discussion: We estimated a population of 496,000 prisoners in MENA, with drug-related offences being a major
cause for incarceration. Twenty countries had data on HIV among incarcerated populations with a median prevalence of 0.6% in
Afghanistan, 6.1% in Djibouti, 0.01% in Egypt, 2.5% in Iran, 0% in Iraq, 0.1% in Jordan, 0.05% in Kuwait, 0.7% in Lebanon, 18.0%
in Libya, 0.7% in Morocco, 0.3% in Oman, 1.1% in Pakistan, 0% in Palestine, 1.2% in Saudi Arabia, 0% in Somalia, 5.3% in Sudan
and South Sudan, 0.04% in Syria, 0.05% in Tunisia, and 3.5% in Yemen. Seven countries had data on HCV, with a median
prevalence of 1.7% in Afghanistan, 23.6% in Egypt, 28.1% in Lebanon, 15.6% in Pakistan, and 37.8% in Iran. Syria and Libya had
only one HCV prevalence measure each at 1.5% and 23.7%, respectively. There was strong evidence for injecting drug use and
the use of non-sterile injecting-equipment in prisons. Incarceration and injecting drugs, use of non-sterile injecting-equipment,
and tattooing in prisons were found to be independent risk factors for HIV or HCV infections. High levels of sexual risk behaviour,
tattooing and use of non-sterile razors among prisoners were documented.
Conclusions: Prisons play an important role in HIV and HCV dynamics in MENA and have facilitated the emergence of large HIV
epidemics in at least two countries, Iran and Pakistan. There is evidence for substantial but variable HIV and HCV prevalence, as
well as risk behaviour including injecting drug use and unprotected sex among prisoners across countries. These findings
highlight the need for comprehensive harm-reduction strategies in prisons.
Keywords: HIV; HCV; incarceration; Middle East and North Africa; prisons; PWID.
Received 15 December 2015; Revised 5 April 2016; Accepted 26 April 2016; Published 27 May 2016
Copyright: – 2016 Heijnen M et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Introduction
HIV and hepatitis C virus (HCV) infections in prisons have been
identified globally as a public health problem [1]. High HIV
prevalence among prisoners has been documented in multiple
countries, with a prevalence of at least 10% in 18 low-income
countries [2]. High HCV prevalence among prisoners has
also been reported across countries with one in four prisoners
globally testing HCV positive [3]. Although HIV and HCV
transmission in prisons is difficult to investigate in epidemio-
logical studies [2], there has been evidence of prisons playing
a role in the emergence and amplification of HIV epidemics
[4]. Prisons have characteristics that can increase the risk of
HIV and HCV exposure, including high rates of injecting drug
use, often with non-sterile injecting equipment, unprotected
sex and use of non-sterile tattooing equipment or razors for
shaving [5,6]. With this context, the recently launched Joint
United Nations Programme on HIV/AIDS (UNAIDS) Strategy
for 2016 to 2021, titled ‘‘On the Fast-Track to end AIDS,’’ has
highlighted, for the first time, a specific global target for HIV
response among incarcerated populations (Target 6) [7].
People who inject drugs (PWID), one of the key populations
at risk of HIV and HCV infections, are often overrepresented
among prison inmates; and imprisonment is a common and
recurring event for many PWID [8,9]. Incarceration of PWID,
who often continue to inject drugs in prison, together with
other risk behaviours, is conducive for a favourable environ-
ment for the transmission of HIV and HCV in prisons.
Injecting drug use is an important transmission route for
HIV and HCV in the Middle East and North Africa (MENA)
[10,11]. This region has several vulnerability factors for the
practice; for example, the majority (80%) of the global supply
of heroin is produced in Afghanistan [12], and over three-
quarters of this is trafficked through Iran and Pakistan [13].
Increased purity and availability of heroin in MENA at lower
cost may have contributed to higher injecting drug use [14].
Recently, emerging HIV epidemics have been documented
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among PWID [10] and men who have sex with men (MSM)
[15] in different MENA countries. The HIV epidemic in MENA
is one of the two fastest growing HIV epidemics worldwide
with most country-specific epidemics emerging only in the last
decade [16]. MENA also appears to have the highest HCV
prevalence in the population at large in the world [17,18]. The
highest HCV prevalence worldwide is found in Egypt at 14.7%
[19,20], followed by Pakistan with one of the largest HCV-
infected populations globally with a national HCV prevalence
of 4.8% [21,22].
Against this global background and regional context of
emerging HIV epidemics in MENA, it is important to assess
HIV and HCV infection levels among prisoners in this region
and establish the role that prisons play in the transmission
dynamics. The aim of this review is to synthesize available
data on HIV and HCV prevalence among prisoners, assess risk
behaviours and risk factors in prisons, and delineate the role
of incarceration in the HIV epidemic dynamics in MENA.
Our overarching goal is to provide a coherent overview of
the status of these infections in prisons that can highlight
opportunities for action and inform resource allocation as well
as HIV and HCV policy and programming priorities.
Methods
This narrative review is based on a compilation and synthesis
of data that relate to HIV and HCV infections and prisons in
MENA. The data have been identified through comprehensive
systematic searches of literature, conducted as part of the
MENA HIV/AIDS Epidemiology Synthesis Project [11,23] and
the MENA HCV Epidemiology Synthesis Project [24]. Data
collection in the MENA HIV/AIDS Epidemiology Synthesis
Project started in mid-2003 with the mandate to collect and
synthesize all available data on HIV, sexually transmitted
infections, and sexual behaviour in MENA through a series of
systematic sub-studies focused on different aspects of the HIV
epidemic [10,11,15,23,2528]. Data collection on the MENA
HCV Epidemiology Synthesis Project started in April 2011
with the mandate to characterize HCV epidemiology in MENA
and estimate country-specific population-level HCV preva-
lence through a series of systematic sub-studies focused on
sub-regional analyses [20,24,2936]. No publication date or
language limitations were set for either of these projects,
and thus, they include all identified and available data for the
region published at any time. As a consequence of these
projects, a substantial volume of data on HIV and HCV
infections and prisons has been identified that warranted
the conduct of the present study. Nearly all these data were
generated and published after 1990, given the relatively
recent discovery of both viruses (in the 1980s), but most
identified and included data in our review were generated
and published after 2000 with the strong growth in HIV and
HCV research in MENA following increased funding for HIV
research thanks to international donors [37] and the growing
interest in HCV infection such as after the discovery of the
large HCV epidemic in Egypt [20].
Data sources for our study included peer-reviewed publica-
tions identified through PubMed and Embase searches and
publications in local and regional journals not indexed in
PubMed or Embase but identified through specific custom
searches (without any language or date restrictions). The
search terms used in the literature searches included
broad geographic, infection, and epidemiological qualifiers
to ensure inclusiveness, as can be seen in different sub-studies
of the two Synthesis Projects [10,11,15,20,2326,2838].
A substantial volume of relevant unpublished country-
level reports and databases were also identified through the
MENA HIV/AIDS Epidemiology Synthesis Project database
[11,23]. Twenty-four countries were included in our defini-
tion of MENA: Afghanistan, Algeria, Bahrain, Djibouti, Egypt,
Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman,
Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan,
South Sudan, Syria, Tunisia, United Arab Emirates (UAE), and
Yemen. Because of the recent independence of South Sudan,
Sudan is mainly referred to as one country in this review,
including Sudan and South Sudan, unless the data allows
otherwise.
Country-level data extracted from studies included HIV
and HCV prevalence and incidence among prisoners,
prevalence of injecting drug use and use of non-sterile
injected equipment in prisons, and prevalence of sexual and
other risk behaviours among prisoners. We also extracted
and summarized measures of association from studies that
investigated history of imprisonment and history of injecting
drug use among prisoners as risk factors for HIV or HCV
infections. Imprisonment rates were extracted from the
International Centre for Prison Studies [39] and complemen-
ted with additional data on country-specific imprisonment
rates from included publications, where applicable. A map of
the region displaying imprisonment rates was developed
using Tableau software (Version 9.2, Seattle, WA, USA). In
text and tables, the numbers of decimal points in all included
percentages were as per the original source, up to one
decimal place. Percentages reported with more than one
decimal place have been rounded to one decimal place. The
only exception to this rule are HIV and HCV prevalence
measures below 0.1%, in which case two decimal places are
provided.
The above data were synthesized using a triangulation
approach [40] to infer key features of HIV and HCV
epidemiology as they relate to incarceration. This approach
consists of an integrated analysis of multiple sources of data
examined side-by-side to draw a comprehensive picture of
HIV and HCV epidemiology and prisons. We estimated the
prisoner population by weighing country-level imprisonment
rates by adult population size, as extracted from the United
Nations Population Division Database [41]. When more than
one prisoner population estimate was available per country,
the median of estimates was used. We described HIV and
HCV prevalence among prisoners in each study included in
the review and summarized them at country-level using the
median and total range of values. In addition, we provided
an overall estimate (median) of HIV/HCV prevalence in the
region and accompanying interquartile range (IQR). All odds
ratios (ORs) included were extracted from multivariable
analyses with adjustment of confounders, unless otherwise
specified.
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Results
Imprisonment and drug use
Imprisonment rates
We estimated that there are 496,000 prisoners across
MENA (no prisoner estimate available for Palestine, therefore
estimate is across 23 countries). As reported by the World
Prison Studies [42], the vast majority of prisoners in MENA
are male. The estimated proportion of females (as percen-
tage of prison population) ranges from 1.6% Yemen to 14.6%
in Qatar [42]. The average imprisonment rate is 114 per
100,000 adults (range: 33/100,000 in South Sudan to 284/
100,000 in Iran; Figure 1). The prison population appears to
be dynamic; it was reported in 2010 that there were as much
as 200,000 prisoners in Iran in 245 prisons and detention
centres, and 450,000 persons were estimated to enter and
exit prisons annually [9]. In Afghanistan, it has been projected
that the prison population will increase to 30,000 persons,
mostly because of drug-related incarceration, by the end of
2015 [43].
Drug-related incarceration and drug use in prison
A strong link between drug use and incarceration has been
documented in MENA. Across different studies, 45 [9], 48
[44], 60 [45], and 98.5% [46] of prison inmates in Iran, 58%
in Sudan [47], and 68% prisoners in Syria [48] were incar-
cerated for drug-related offences. Similarly, 30.2% of PWID
in Lebanon [49], and 61 to 83% of different male PWID
populations in Oman [50] were incarcerated for drug-related
offences. It was estimated that more than 400,000 people are
arrested in Iran annually on drug-related charges [51], though
a large proportion are not expected to serve long sentences,
resulting in a high prisoner turnover [52].
In Iran and Sudan, 64% [44] and 26.1% [47] of prisoners
reported a history of drug use. Continued use of drugs while
in prison was reported by 67% of incarcerated drug users in
Algeria [53]; 18.7% [54] and 91% [55] in Iran; 26 to 44% in
Oman [50]; 15.1% [56] and 59.2% [57] in Pakistan; and 22%
in Syria [58]. Similarly, history of previous incarceration was
reported by over half of PWID [59] in Afghanistan; 40.4 [60],
41.0 [55], 75.3 [54], 76.2 [61], and 94.0% [62] in Iran; 45.9%
in Morocco [63]; and 14.0 [64], 33 [65], 40.0 [64], and 84.0%
[57] in Pakistan.
Risk behaviours and incarceration
Injecting drug use and incarceration
Injecting drug use in prison appears to be present in several
countries. Injecting drugs while incarcerated was reported
by 17.4% of PWID in Afghanistan [59]; 23.2% in Egypt [66];
6.6% [54], 27.6 to 53.6% [67], and 85% [55] in Iran; 19.8% in
Morocco [63]; 5 to 11% in Oman [50]; and 11% in Syria [48].
Similarly, 2.2% of prisoners in Sudan [47] and 0.2% of prisoners
(12% of whom were PWID) in Lebanon [68] injected drugs in
prison. Several reports indicated initiation of drug injection
in prisons. In Iran, for example, 5.7% of newly admitted
prisoners and 21.3% of existing inmates started injecting while
in prison [67].
Use of non-sterile injecting equipment in prisons has been
reported by 30% of PWID in Afghanistan [69]; 6.1 [70], 12 [71],
16.8 [72], 27.1 [54], 36 [73], 47.3 [74], and 48.5% [61] in Iran;
7% in Lebanon [49]; 3 to 11% in Oman [50]; 46% in Pakistan
[57]; and 80% in Syria [48]. In Sudan, 3.2% of prisoners
reported use of non-sterile syringes while in prison [75].
Sexual risk behaviour and incarceration
High levels of sexual risk behaviour among prisoners have
been documented both before and during imprisonment.
Premarital and/or extramarital sex was reported by 11.4 [75],
41.9 [76], and 65.2% [47] of prisoners in Sudan and by 62.5% in
Pakistan [56]. Among juveniles imprisoned in Pakistan, 76.4%
reported sex before incarceration [77]. Sex with multiple
partners was reported by 17.7% of prisoners in Sudan (3
Figure 1. Imprisonment rate and prison population in countries of the Middle East and North Africa.
Circles present a visual representation of the estimated size of the prison population. The number of prisoners is presented below the circle for
each country. No data on imprisonment rate or prison population were available for Palestine.
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partners) (no timeframe specified) [75]. The average number
of sexual partners was 5.2 (lifetime) among female prisoners
in Morocco [78] and 16.7 among prisoners who were sexually
active during the last year in Syria [58].
Sex with another male was reported by 1.6% of male
prisoners in Iran [67], 19.3% in Pakistan [77], and 28.8% in
Sudan [75]. In one study in Pakistan, 21.3% of male prisoners
reported paying for sex with a male [57]. Sex with a female
sex worker was reported by 21.6% and 28.5% of prisoners in
two different settings in Afghanistan [43]; 11.9% in Iran [67];
45.9% in Pakistan [57]; and 8.6% in Sudan [76]. In Syria, 21%
of prisoners reported selling sex [58].
Overall, there was a history of low condom use among
prisoners prior to incarceration. Only 4% [76] and 11.6% [75] of
prisoners in Sudan ever used condoms. In Morocco, 9% of
female prisoners reported using condoms [78], while in Syria,
10.5% of prisoners used a condom during last sex [57].
Condom use with casual partners was reported by 18.2%
of prisoners in Pakistan [56] and 5.6% in Sudan [47]. In Iran,
16.7% of male prisoners used condoms with a male in
the year prior to incarceration [67]. Condom use during
commercial sex was reported by 27.3% of prisoners in Iran
[67] and 24.7 [57] and 9.1% (with male sex workers) [57] in
Pakistan.
There is evidence of sexual acts between males, mostly
unprotected, happening in prisons. Among imprisoned male
juveniles in Pakistan, 22.7% had sex in prison [77], whereas in
Oman 6 to 18% of different male PWID populations reported
doing so without condoms [50]. In Sudan, 31% of prisoners
reported sex in prisons, and 28.8% reported this sex to be
between males [75]. Anal sex with another male in prison
was reported by 5.4% of male prisoners in Iran [53], 1.9 [79]
and 2.6% [68] in Lebanon, and 1.4% in Sudan [47]. In Iran,
62.1% of prisoners did not use a condom during their last
sexual contact in prison, and 18.5% reported having sex for
money or drugs with at least two sexual partners [70]. Sexual
abuse/forced sex by other prisoners has been also reported
[44], by 10.3% of prisoners in Syria [58].
Tattooing and use of non-sterile razors and incarceration
Different studies reported a history of tattooing among
prisoners, though few reported actual tattooing in prison.
In Lebanon, 2.3% of prisoners had a tattoo done in prison
[79], compared with 12.9% in Iran [52]. Also in Iran, 25.0 [67]
and 40.6% [62] of imprisoned PWID reported being tattooed
in prison. It was reported that 23.6 [61] and 31% [80] of
prisoners in Iran, 26.7% in Pakistan [57], and 23.4% in Sudan
shared or re-used shaving razors/blades in prison [75].
Incarceration and risk of exposure to HIV and HCV infections
Risk behaviours in prison, such as injecting drugs, use of non-
sterile injecting equipment, tattooing, and use of non-sterile
toiletries, have been documented as modes of HIV and HCV
exposure.
Incarceration as a risk factor for HIV and HCV
Largely because of injecting drug use, prior incarceration has
been reported as a risk factor for both HIV and HCV in MENA,
though most evidence originates from Iran. Here, imprisoned
PWID with a history of previous incarceration had 2.9 to 4.0
[67] the odds of HIV infection compared with those entering
prison for the first time, with higher OR observed with
increased number of prior incarcerations [67].
Similarly, repeated incarceration was significantly asso-
ciated with HCV infection among prisoners in two studies in
Iran [81] and Lebanon [79] (analyses at bivariate level). After
adjusting for other confounders, previous incarceration was
significantly associated with HCV infection in three other
studies from Iran. PWID in a mandatory detention centre had
four times the odds of being HCV positive if they were
previously incarcerated (OR of 4.4) [54]. Among imprisoned
drug users, the OR of HCV infection was 3.1 and 6.7 for those
who had 2 to 5 and 5 previous incarcerations, respectively,
compared with new entrants [82]. Similarly, length of lifetime
incarceration was significantly associated with HCV infection
with ORs of 2.4 and 3.4 for those incarcerated for a total
of 7 to 12 months and more than 12 months, respectively,
compared with those who had never been incarcerated or
been in prison for B6 months [83].
Imprisonment was also found to be a significant risk factor
for HIV and HCV co-infection among incarcerated PWID in
Iran (OR of 7.5) [84].
History of injecting risk behaviour among incarcerated
populations as a risk factor for HIV and HCV infections
Different studies among incarcerated populations, but mostly
from Iran, have linked injecting drug use to HIV or HCV
exposure. In a male prison setting in Pakistan, injecting drug
use was found to be a significant predictor of infection,
irrespective of whether it was HIV, HCV, or hepatitis B virus
(OR of 24.3) [57]. In Iran, history of drug injection was
associated with 4.5 [85] and 7.8 [52] increased odds of HIV
infection among prisoners, and injecting drugs in prison was
found to be the greatest risk factor for HIV infection among
incarcerated PWID (OR of 6.7) [67]. Similarly, history of using
an opioid in jail in Iran was a risk factor for HIV infection (OR
of 2.1) [86].
A number of studies of prisoners in different countries
reported ORs of 4.1 [87], 8.1 [82], 14.7 [85], 24.7 (females)
[88], and 134.4 (juvenile inmates) [81] for injecting drug use
as a risk factor for HCV infection. Incarcerated prisoners who
injected drugs had a significantly higher HCV prevalence
compared with non-injecting prisoners (46.4% versus 2.0%)
[56]. Age at first injection was found to be a significant risk
factor for HCV among prisoners; first injection before the age
of 25 resulted in 2.7 times the odds of infection [54].
History of use of non-sterile injecting equipment among
incarcerated populations as a risk factor for HIV and HCV
infections
Among incarcerated PWID in Iran, use of non-sterile syringes
resulted in a significantly increased risk of HIV and HCV co-
infection (OR of 4.5) [84]. Also in Iran, use of non-sterile
needles was a significant risk factor for HIV in a prison setting
(OR of 5.3) [67]. In Pakistan, history of use of non-sterile
needles/syringes was the main risk factor for HIV infection
among incarcerated PWID (OR of 2.0) [89].
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History of tattooing or use of non-sterile razors as risk
factors for HIV or HCV infections
Tattooing inside prison was associated with an increased risk
of HIV infection (OR of 1.3 [62] and 1.8 [67] in Iran, and 2.8 in
Egypt [87]) and HCV infection (OR of 2.0 in Iran) [83]. History
of tattooing was found to be a significant risk factor for HCV
infection in other studies in Iran including among prisoners
(OR of 2.1 [52] and 100 [80]) and imprisoned PWID (OR of
1.8 [82], 2.3 [67], and 2.3 [54]).
Tattooing and use of non-sterile toiletries (brushes and
razors)were found to be significant risk factors forHIV infection
in an Egyptian prison (tattooing: OR of 2.8; toiletries: OR of 3.9)
[87]. Use of non-sterile razors was found to be a significant
predictorofHCV infection in a Pakistani prison (ORof 18.0) [56].
HIV and HCV infections among prisoners
HIV outbreaks in MENA prisons and the HIV epidemic
Outbreaks of HIV in prisons have been documented globally
[2] and prisons have played a role in the emergence of
HIV epidemics in different countries [4,6]. The MENA region is
no exception where there is evidence that outbreaks of HIV
in prisons, specifically in Iran and Pakistan, were the catalysts
of the large HIV epidemics seen among PWID.
The first HIV case among PWID in Iran was reported in
1992 [90]. Few cases were reported in the three following
years [90]; however, starting from 1996, the number of
reported cases suddenly rose 30-fold, which appeared to be
linked to HIV outbreaks in prisons [90,91]. In Kermanshah
prisons, the first HIV case was reported in 1995, followed
by 58 cases in 1996 and increasing to 407 cases in 1997 to
1998 [92].
Following these prison HIV outbreaks, HIV prevalence
started rising among PWID across Iran regardless of incarcera-
tion. By 2003, HIV prevalence reached concentration stage
in most surveys (HIV prevalence 5%) [91]. Through over-
lapping risk behaviours [10,15,67,91,9395], HIV was intro-
duced to the sexual networks of MSM [15,96] and
heterosexual commercial sex [94,9799]. HIV transmission to
spouses of PWID increased; the contribution of spouses to the
number of notified HIV cases increased four-fold from 0.5% of
all cases in 2001 to 2% in 2004 [91]. The vast majority of
infected women in Iran acquired the infection from their
(predominantly PWID) HIV-infected husbands [100102].
Similar evolution of the HIV epidemic occurred in Pakistan.
After years of virtually zero HIV prevalence among PWID
[10,103106], an HIV outbreak was identified among PWID in
a prison in 2003. Immediately thereafter, HIV started a rapid
growth among PWID across Pakistan regardless of incarcera-
tion [107109]. In Karachi, for example, HIV prevalence in
2004 increased from less than 1 to 23% in less than six
months [110] and reached 42% by 2011 [108]. Today, the
HIV epidemic among PWID in Pakistan is one of the world’s
largest. Through overlapping risk behaviours, the epidemic
among PWID appears to have ignited an HIV epidemic among
MSM and transgender people [10,15,28]. Predictably, spouses
of PWID were affected, with the majority of infected women
acquiring HIV from their infected spouses [111].
HIV and HCV prevalence and incidence among prisoners
in MENA
Data on HIV prevalence in prison were identified in 20
countries, with no data available in Algeria, Bahrain, Qatar,
and UAE. Only one study, from Iran, provided data on HIV
incidence, measuring an annualized incidence rate of 16.8%
in a mandatory detention centre in Tehran [112]. Data on
HCV prevalence in prison were identified in seven countries:
Afghanistan, Egypt, Iran, Lebanon, Libya, Syria, and Pakistan.
The countries that contributed the largest number of data
points were Iran, Morocco, and Pakistan; and HIV and HCV
prevalence data from these countries are listed in Table 1.
HIV and HCV prevalence data from the remaining countries
are listed in Table 2. HIV and HCV prevalence data among
prisoners at the country-level are further summarized in
Figure 2. As can be seen from the tables, the majority of
prevalence data points referred to both males and females
(n71), with 36 prevalence data points specifically reporting
on male prisoners and 22 data points specifically reporting on
female prisoners.
There was considerable variation in HIV and HCV prevalence
among incarcerated populations, both within and between
MENA countries (Tables 1 and 2, Figure 2). The median
HIV prevalence among incarcerated populations was 0.6% in
Afghanistan (range: 0.211.0), 6.1% in Djibouti (range:
5.017.0), 0.01% in Egypt (range: 01.6), 0.1% in Jordan
(range: 00.1), 2.5% in Iran (range: 063.0), 0.05% in Kuwait
(range: 00.5), 0.7% in Lebanon (range: 0.21.6), 18.0% in
Libya (range: 060.0), 0.7% in Morocco (range: 03.1), 0.3% in
Oman (range: 0.172.0), 1.1% in Pakistan (range: 0.0310.0),
1.2% in Saudi Arabia (range: 0.027.0), 5.3% in Sudan and
South Sudan (range: 027.1), 0.04% in Syria (range: 00.4),
0.05% in Tunisia (range: 00.4), and 3.5% in Yemen (range:
044.4).
The median HCV prevalence among incarcerated pop-
ulations was 1.7% in Afghanistan (range: 1.04.6), 23.6% in
Egypt (range: 15.831.4), 28.1% in Lebanon (range: 3.4
52.8), 15.6% in Pakistan (range: 12.818.4), 37.8% in Iran
(range: 2.780.5), 1.5% in Syria, and 23.7% in Libya.
Across all countries, the median HIV prevalence was 0.9%
(IQR: 0.12.8) and the median HCV prevalence was 23.7%
(IQR: 6.345.2).
Synthesis and triangulation of epidemiologic evidence
Figure 3 shows a schematic illustration of the synthesis and
triangulation of the epidemiologic evidence for HIV and
HCV and incarceration in MENA. There is a large incarcerated
population of about half a million prisoners in this region,
with drug use often the cause of incarceration. Prisoners
engage in risk behaviours that expose them to HIV and HCV.
These behaviours, which are often initiated before imprison-
ment, are continued in prison and have been linked to HIV and
HCV exposures during incarceration. Among these behaviours
are use of non-sterile injecting equipment, drug use, multiple
sexual partnerships and unprotected sex, and tattooing and
use of non-sterile razors.
Incarceration in MENA has been documented to be an
independent risk factor for HIV and HCV infections. These
infections have been shown to have a much higher prevalence
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Table 1. Prevalence of HIV and HCV in prisons in Iran, Morocco, and Pakistan
Country Reference
Year of
estimate
HIV prevalence
(%)
HCV prevalence
(%) Sex Drug-use status
Iran Behrooz, 2011 [115] Unknown  54  PWID
Kaffashian, 2011 [116] Unknown  42.0  PWID and non-PWID
Afshar, 2005 [44] Unknown  4060 Both Mostly PWID
Nassirimanesh, 2002 [117] Unknown  78  
Haghdoost, 2013 [92] 19912007 2.8   PWID and non-PWID
Zali, 2001 [118] 1995  45.0 Males PWID
Rahimi-Movaghar, 2012 [119] 19982006 11.8  Both PWID
Amin-Esmaeili, 2012 [120] 19982007 0.4  Both Non-PWID
Shabazi, 2014 [121] 1999 1.56  Both PWID and non-PWID
Shabazi, 2014 [121] 2000 1.81 Both PWID and non-PWID
Zakizad, 2009 [80] 2001  30.8 Males PWID and non-PWID
Rowhani-Rahbar, 2004 [122] 2001 6.9 59.4  PWID
UNAIDS, 2002 [123] 2001 12.063.0   PWID
Khani, 2003 [71] 2001 1.2 47.7 Males PWID and non-PWID
Shabazi, 2014 [121] 2001 3.12  Both PWID and non-PWID
Mir-Nasseri, 2011 [84] 20012002 17.0 80.5 Both PWID
Davoodian, 2009 [124] 2002 15.1 64.8  PWID
Jahani, 2005 [94] 2002 0 2.7 Females PWID and non-PWID
Shabazi, 2014 [121] 2002 3.83  Both PWID and non-PWID
Alizadeh, 2005 [72] 2002 0.9 30.0 Both PWID and non-PWID
Afshar, 2005 [44] 2002 2.1  Both Mostly PWID
Behnaz, 2007 [125] 20022003 5.8 23.1 Both PWID and non-PWID
Javadi, 2006 [73] 2003  35.8 Males PWID and non-PWID
Javadi, 2007 [126] 2003 6.6 37.8 Males 
Pourahmad, 2007 [85] 2003 6.4 34.7 Males PWID and non-PWID
Shabazi, 2014 [121] 2003 2.78  Both PWID and non-PWID
Afshar, 2005 [44] 2003 2.3  Both Mostly PWID
Farhoudi, 2003 [67] 2003 22.0  Males PWID (newly arrived prisoner)
Farhoudi, 2003 [67] 2003 6.0  Males PWID (newly arrived, never
incarcerated)
Farhoudi, 2003 [67] 2003 24.0  Males PWID (existing prisoner)
Amiri, 2007 [82] 2003  45.4 Males PWID and non-PWID
Azarkar, 2007 [127] 2004 0 8.4 Males PWID and non-PWID
Azarkar, 2007 [127] 2004 0 5.1 Females PWID and non-PWID
Shabazi, 2014 [121] 2004 3.05  Both PWID and non-PWID
Afshar, 2005 [44] 2004 3.3  Both Mostly PWID
Ghannad, 2009 [128] 20042005 2.5   
Ghannad, 2009 [128] 20042007 2.4   
Shabazi, 2014 [121] 2005 3.24  Both PWID and non-PWID
Alavi, 2012 [129] 20052006 50.2  Males PWID
Alavi, 2012 [129] 20052006 10.4  Males Inhalant drug users
Alavi, 2012 [129] 20052006 7.6  Males Oral drug users
Ghannad, 2009 [129] 20052006 2.4   
Shabazi, 2014 [121] 2006 2.83  Both PWID and non-PWID
Kheirandish, 2009 [54] 2006  80.0 Males PWID
Kheirandish, 2010 [86] 2006 24.4  Males PWID
Ghanbarzadeh, 2006 [46] 2006 0  Females PWID and non-PWID
Ghannad, 2009 [128] 20062007 1.9   
Shabazi, 2014 [121] 2007 1.71  Both PWID and non-PWID
Kazerooni, 2010 [70] 2007 6.6  Males PWID
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Table 1 (Continued )
Country Reference
Year of
estimate
HIV prevalence
(%)
HCV prevalence
(%) Sex Drug-use status
WHO, 2012 [130] 2007 1.5   
WHO, 2012 [130] 2008 2.8   
Shabazi, 2014 [121] 2008 2.01  Both PWID and non-PWID
Azarkar, 2010 [131] 2008 0 8.1 Both PWID and non-PWID
Nokhodian, 2012 [81] 20082009  4.4 Both PWID and non-PWID
WHO, 2012 [130] 2009 1.6   
Dibaj, 2013 [89] 2009 4.6   PWID
Shabazi, 2014 [121] 2009 1.54  Both PWID and non-PWID
Navadeh, 2013 [52] 2009 2.1  Both PWID and non-PWID
Nokhodian, 2012 [88] 2009 0 7.4 Females PWID and non-PWID
Kassaian, 2012 [132] 2009  41.6 Both PWID and non-PWID
WHO, 2012 [130] 2010 1.4   
Shabazi, 2014 [121] 2010 1.37  Both PWID and non-PWID
WHO, 2012 [130] 2011 2.9   
Shabazi, 2014 [121] 2011 1.28  Both PWID and non-PWID
WHO, 2012 [130] 2011 0.7   
WHO, 2012 [130] 2012 1.6   
Morocco Elharti, 2001 [133] 2001 0.7  Males 
Elharti, 2001 [133] 2001 0  Females 
Khattabi, 2005 [134] 2001 2.3  Females 
Khattabi, 2005 [134] 2002 1.18  Males 
Khattabi, 2005 [134] 2002 0.72  Females 
Khattabi, 2005 [134] 2002 3.14  Females 
Ministry of Health, 20032004 [135] 2003 0.83  Males 
Khattabi, 2005 [134] 2003 0  Females 
Khattabi, 2005 [134] 2003 2.03  Females 
El Ghrari, 2007 [78] 2004 2.0  Females PWID and non-PWID
Khattabi, 2005 [134] 2004 1.2  Females 
Khattabi, 2005 [134] 2004 0.9  Females 
Khattabi, 2005 [134] 2004 0.61  Males 
Bennani, 2006 [136] 2005 0  Females 
Bennani, 2006 [136] 2005 0.61  Males 
Bennani, 2006 [136] 2005 2.94  Females 
Ministry of Health, 2010 [137] 2006 2.1  Females 
Ministry of Health, 2010 [137] 2006 0.53  Males 
Ministry of Health, 2010 [137] 2008 0.77  Males 
Ministry of Health, 2010 [137] 2008 0  Females 
Ministry of Health, 2010 [137] 2009 0.73  Females 
WHO, 2012 [130] 2009 0.4   
WHO, 2012 [130] 2010 0.5   
Pakistan Mujeeb, 1993 [138] Unknown 1.64  Both 
Butt, 2010 [56] Unknown  18.4 Males PWID and non-PWID
Baqi, 1998 [103] 19931994 0.03  Males PWID and non-PWID
Baqi, 1998 [103] 19931994 1.1  Females Non-PWID
Safdar, 2009 [139] 2006 2.8  Both 
Safdar, 2009 [139] 2006 0.7  Males 
Safdar, 2009 [139] 2006 10.0  Females 
Safdar, 2009 [139] 2006 0.5   
Safdar, 2009 [139] 2006 0.4   
Safdar, 2009 [139] 2006 0.5   
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among incarcerated populations (Tables 1 and 2) than among
the general population in this region [11,23]. With the
usually short sentences for drug use and repeated imprison-
ments, there are active infection transmission links between
prisons and community. These links have facilitated the
spread of HIV and HCV to wider at-risk populations, such as
when HIV outbreaks have occurred in prisons. Indeed, HIV
outbreaks in the prisons of Iran and Pakistan have played a
critical role in igniting large-scale HIV epidemics among PWID
in different parts of these two countries. Despite the progress
in understanding the dynamics of HIV and HCV and imprison-
ment in several countries, the situation remains poorly
understood in over half of MENA countries because of limited
epidemiologic evidence.
Discussion
Prisons play an important role in the dynamics of HIV and HCV
infections in MENA and have facilitated the emergence of
large HIV epidemics in at least two countries. Incarceration is a
main risk factor for HIV and HCV in this region. The prison
environment is conducive to different forms of risk behaviour
that expose prisoners to HIV and HCV; and these have been
documented to be prevalent in MENA. The most important of
these behaviours is injecting drug use. Drugs appear to be
accessible in MENA prisons, though at a higher cost. In Iran,
drugs were found to be 5 to 8 times more expensive in prisons
than outside [113], which has been suggested as a reason
for initiation of drug injection, as taking drugs through
injection is more cost-effective [113,114]. The scarcity of
raw opium and difficulty in hiding smoking are other factors
promoting drug injection in prisons [54,55]. The in and out of
prison transmission links appear to contribute significantly
to HIV and HCV transmission in the wider at-risk populations
in at least few countries. With the currently emerging HIV
epidemics among PWID and MSM in different MENA
countries, some of which have already reached substantial
levels [10,15,28], prisons may play a growing role in the
dynamics of infection transmission.
We estimated that there are approximately half a million
prisoners in MENA. Prison populations vary considerably,
with the regional average of 114 prisoners per 100,000 adults
falling just below the global average of 144 per 100,000 [39].
Most of the prisoners in the MENA region are males [42],
and the majority of the studies included in this review were
conducted either among males or both sexes. Some countries
did provide data on infection prevalence among female
prisoners, such as Morocco [27], but it must be noted that
even the World Prison Study report provided estimates of
female prisoners in only 12 MENA countries [42].
A substantial proportion of these prisoners have been
convicted of drug-related offences. The high HCV prevalence
among prisoners, with a median of 24% across countries
(Tables 1 and 2), further indicates that a large fraction of
prisoners inject or injected drugs in the past. In a context of
over 600,000 PWID in MENA [10], injecting drug use poses a
major challenge. PWID continue to injected while incarcer-
ated, often using non-sterile needles/syringes. While it
appears to be the main mode of HIV/HCV exposure among
prisoners, considerable sexual risk behaviour is also reported,
as well as tattooing and use of non-sterile razors/toiletries.
These may also contribute to HIV and HCV exposures.
The convergence of vulnerability and risks in prison is not
unique to the region; similar situations have been reported
in both developing [87,121,166] and developed countries
[167169]. HIV and HCV prevalence levels among incarcer-
ated populations in MENA are also broadly consistent with
those found globally [13]. Prisoners often practice high
injecting and sexual risk behaviours even before incarcera-
tion; and the majority of prisoners come from vulnerable
strata of society suffering from poorer health and fewer
opportunities [169].
There is generally poor access in MENA to services that can
reduce prisoners’ risk of infection exposure. Iran has made
significant progress in implementing and expanding harm-
reduction services in prisons, including needle exchange and
methadone maintenance programmes [112]. Morocco has
made plans for methadone replacement therapy in prisons
[170]. Conjugal visiting rooms have been provided in some
prisons in Iran and Sudan [75,91], although in Sudan the
right to conjugal visits is rarely practiced [75]. The progress in
the public health response in few countries, though modest,
serves as an example of what could be feasible in other
Table 1 (Continued )
Country Reference
Year of
estimate
HIV prevalence
(%)
HCV prevalence
(%) Sex Drug-use status
Safdar, 2009 [139] 2006 0.3   
Safdar, 2009 [139] 2006 2.1   
Safdar, 2009 [139] 2006 0.7   
Pakistan Safdar, 2009 [139] 2006 1.0   
Kazi, 2010 [57] 20072008 2.0 15.2 Males PWID and non-PWID
Gorar, 2010 [140] 20082009  12.8  
Shah, 2013 [141] 2009 2.4  Males 
Nafees, 2011 [142] 2009 2.01  Both 
Anwar, 2011 [143] 2009  15.9 Both 
PWID, people who inject drugs.
‘‘ ’’ represents not reported or unclear in the original data source.
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Table 2. Prevalence of HIV and HCV among incarcerated populations in MENA countries, excluding Iran, Morocco, and Pakistan
Countrya Reference
Year of
estimate
HIV prevalence
(%)
HCV prevalence
(%) Sex Drug-use status
Afghanistan World Bank, 2008 [144] 2008 11.0  Male PWID
National AIDS Control Program, 2010 [145] 2009 0.6 1.7  
National AIDS Control Program, 2010 [145] 2009 1.6 4.1  
WHO, 2013 [146] 2011 0.25 0.98  
WHO, 2012 [130] 2011 0.2   
WHO, 2012 [130] 2012 0.5 4.6  
WHO, 2012 [130] 2012 0.8 1.4  
Djibouti Shresta, 1999 [147] 1993 6.1  Both 
Shresta, 1999 [147] 1993 5.0  Male 
Shresta, 1999 [147] 1993 17.0  Females 
Egypt El-Ghazzawi, 1987 [148] Unknown 0  Both 
Mohamed, 2013 [87] Unknown 0 15.8 Both PWID and non-PWID
Ministry of Health, 2001 [149] 19862001 0.01   
HIV/AIDS Surveillance database (US Census
Bureau), 2013 [150]
19911999 0  Both 
Quinti, 1995 [151] 19921994 1.6 31.4  
Murugasampillay, 1995 [152] 1993 0  Both 
HIV/AIDS Surveillance database (US Census
Bureau), 2013 [150]
2004 0.02  Both 
WHO, 2012 [130] 2008 0.22 
WHO, 2012 [130] 2008 2.8   
WHO, 2012 [130] 2009 1.6   
WHO, 2012 [130] 2010 1.4   
WHO, 2012 [130] 2011 0.7   
WHO, 2012 [130] 2012 1.6   
Iraq Shrestha, 1999 [147] 19931999 0   
WHO, 2012 [130] 2010 0   
Jordan El-Tayeb, 1995 [150] 1987 0.14  Both 
El-Tayeb, 1995 [150] 1990 0.05  Both 
El-Tayeb, 1995 [150] 1991 0.2  Both 
WHO, 2012 [130] 20072010 0   
Kuwait Kuwait National AIDS program [150] 19841998 0.05   
Shreshta, 1999 [147] 1993 0.14  Both 
Shreshta, 1999 [147] 1994 0.11  Both 
Shreshta, 1999 [147] 1995 0  Both 
Shreshta, 1999 [147] 1996 0  Both 
Shreshta, 1999 [147] 1997 0.09  Both 
Shreshta, 1999 [147] 1998 0  Both 
Shreshta, 1999 [147] 1999 0  Both 
UNAIDS, 2004 [153] 1999 0.52  
UNAIDS, 2004 [153] 2000 0  
WHO, 2012 [130] 2011 0.11  
Lebanon Shreshta, 1999 [147] 1993 1.16  Both 
Shreshta, 1999 [147] 1994 1.63  Both 
Shreshta, 1999 [147] 1995 0.72  Both 
National AIDS Control Programme [154] 20072008  52.8  PWID and non-PWID
Mishwar, 2008 [68] 20072008 0.16  Males PWID and non-PWID
Mahfoud, 2010 [79] 20072008 0.17 3.4 Males PWID and non-PWID
Libya Sammud, 2005 [155] Unknown 18.0   
Shazly, 1991 [156] 1990 0  Both 
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countries to enhance provision of sterile injecting equipment,
methadone replacement therapy, HIV antiretroviral therapy,
HCV treatment, condoms, and information to prevent HIV
and HCV infections.
HIV and HCV voluntary counselling and testing needs to be
made available to incarcerated populations along with harm
reduction and treatment services. These services should be
integrated within the wider scope of public health services
for PWID, MSM, and commercial sex workers. Initiation of
prevention and treatment services in prisons may provide an
opportunity for expanding these services outside prisons.
Prisons present a unique entry point for intervention, because
Table 2 (Continued )
Countrya Reference
Year of
estimate
HIV prevalence
(%)
HCV prevalence
(%) Sex Drug-use status
Shazly, 1991 [156] 1990 0.51  Both 
Dolan, 2007 [2] 2003 60.0   PWID
Ziglam, 2012 [157] 2006 18.4 23.7 Males 
Oman Shreshta, 1999 [147] 1996 2.01  Both 
Shreshta, 1999 [147] 1997 1.3  Both 
Shreshta, 1999 [147] 1998 0.28  Both 
Shreshta, 1999 [147] 1999 0.17  Both 
WHO, 2012 [130] 2007 0.4  
WHO, 2012 [130] 2008 0.3   
WHO, 2012 [130] 2009 0.8   
WHO, 2012 [130] 2010 0.3   
WHO, 2012 [130] 2011 0.3   
Palestine WHO, 2012 [130] 2010 0   
Saudi Arabia Madani, 2004 [158] 19842001 7.0   
WHO, 2012 [130] 2010 0.02   
WHO, 2012 [130] 2011 1.3   
Ministry of Health, 2014 [159] 2012 1.16   
Somalia Ahmed, 1997 [160] 1997 0  Males 
Sudan/South Burans, 1990 [161] 1988 (?) 0   
Sudan UNAIDS, 2004 [162] 2002 2.0   
Assal, 2006 [75] 2005 5.3  Males 
Assal, 2006 [75] 2005 8.63  Both 
Assal, 2006 [75] 2005 27.1  Females 
Syria Shrestha, 1999 [147] 1993 0.07  Both 
Shrestha, 1999 [147] 1994 0.44  Both 
Shrestha, 1999 [147] 1995 0  Both 
Shrestha, 1999 [147] 1996 0.2  Both 
Shrestha, 1999 [147] 1997 0  Both 
Shrestha, 1999 [147] 1998 0  Both 
National Progress report on AIDS,
2012 [163]
2011 0.22   
Ministry of Health, 2014 [58] 20132014 0 1.5 Both 
Tunisia Gharbi, 1988 [164] 1987 (?) 0.42  Both 
Ministry of Health, 1990 [165] 19881989 0.05  Both
Shrestha, 1999 [147] 19941999 0  Both 
Yemen Shrestha, 1999 [147] 19931994 0  Both 
Shrestha, 1999 [147] 1995 3.53  Both 
Shrestha, 1999 [147] 1996 1.64  Both 
Shrestha, 1999 [147] 1997 44.43  Both 
Shrestha, 1999 [147] 1998 26.53  Both 
aNo data available for Algeria, Bahrain, Qatar, and UAE.
PWID, people who inject drugs.
‘‘ ’’ represents not reported or unclear in the original data source.
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many of the incarcerated individuals are part of the most
at-risk ‘‘hidden’’ populations. Prisoners, upon release, could be
enlisted to serve as interpersonal communication agents within
their communities. Lastly, reduction in prison populations and
less reliance on incarceration as a punishment should be
considered.
Our study has several limitations. The data synthesized
in this review were not extracted strictly through a specific
systematic search of data on HIV/HCV in prisons. However, it
is unlikely that we have missed consequential evidence
that would affect our results and findings. The data were
identified through broad and comprehensive systematic
Figure 2. HIV and HCV prevalence among incarcerated populations in MENA countries.
Three outliers (prevalence 40%; Iran (n2) and Libya (n1)) were removed from Figure 2a to improve display.
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searches of different aspects of HIV and HCV epidemiology in
MENA through two large-scale projects; in fact, the most
comprehensive epidemiology projects for both infections in
this region to date. It is possible that a systematic search of
HIV/HCV in prisons may not have yielded as much data, as
most data synthesized here were extracted from studies not
focused on prisoners, but on other populations such as
PWID. These studies could have been missed in a systematic
search focusing strictly on HIV/HCV in prisons.
Nearly all included studies were cross sectional, making it
difficult to discern temporal patterns and direct evidence
of HIV/HCV incidence within prisons. The availability of data
varied considerably between countries. A large fraction of
data originated from only three countries: Iran, Morocco, and
Pakistan. Hardly any meaningful data were identified for
few countries. Though some studies reported prevalence
data from a range of sites, many were conducted in a small
number of prisons; these results may not be generalizable to
the wider prison population of that country. Included studies
may also suffer from limitations and biases; and the reporting
quality varied across studies. The illegal and sensitive nature
of risk behaviours, as well as social desirability, may have
biased reported results in included studies, especially those
with questions pertaining to sexual behaviour in an all-male
environment. A number of studies highlighted the exclusion
of questions about sexual behaviour in prison as a limitation
of their data collection [58,72,79,82,87,142].
Our results show considerable heterogeneity, both in terms
of risk behaviours and prevalence of HIV/HCV infections. This
heterogeneity is likely to reflect true differences in the specific
composition of the incarcerated populations from one setting
to another, within or across countries. The representation
of specific at-risk populations such as PWID or FSW can vary
immensely from one setting to another; Iran, for instance, is
much more affected by injecting drug use than Morocco [10].
Conclusions
HIV and HCV prevalence among incarcerated populations in
MENA vary considerably, but the risk factors for infection are
present throughout the region. Prisons have played an
important role in HIV and HCV dynamics and have facilitated
the emergence of large HIV epidemics in Iran and Pakistan.
Prisons could be playing a disproportionately larger role in HIV
dynamics in MENA than elsewhere, as highlighted recently by
UNAIDS [7]. The need to ensure access to HIV combination
prevention services for at least 90% of prisoners by 2020
has been emphasized in the new UNAIDS strategy for 2016
to 2021 [7]. Despite this global push for improved services
in prisons, regional response continues to lag needs. It is
critical to expand access to harm reduction and treatment
services, as well as HIV and HCV treatment. Increased and
expanded HIV and HCV surveillance in prisons is also essential,
for example through integrated bio-behavioural surveys.
The status of these infections in prisons in several MENA
countries continues to be poorly understood. By implement-
ing prevention and care activities, and carefully monitoring
these infections in prisons, these institutions could play a
pivotal role in the control of, and eventual reduction in, HIV
and HCV transmission well beyond prison settings.
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